Skip to search formSkip to main contentSkip to account menu

selumetinib

An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein… 
National Institutes of Health

Related topics

Related topics

6 relations
ARRY 142886Inhibition of Cell ProliferationMAP3K1 protein, humanNCIt Antineoplastic Agent Terminology

Broader (1)

AZD 6244

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Selumetinib Inhibits Melanoma Metastasis to Mouse Liver via Suppression of EMT-targeted Genes.
AIM We investigated the therapeutic effects of a mitogen-activated protein (MEK) inhibitor, selumetinib, in a hepatic melanoma… 
2016
2016
SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
10503Background: PN in NF1 can cause substantial morbidity, and there are no approved medical therapies. In a phase I trial of… 
2016
2016
High-Content Imaging Platform for Profiling Intracellular Signaling Network Activity in Living Cells
2014
2014
Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).
10018 Background: Lack of functional neurofibromin in NF1 leads to dysregulated Ras and tumorigenesis. Selumetinib (AZD6244; ARRY… 
2014
2014
Molecular Pathways Associated with Aggressiveness of Papillary Thyroid Cancer
The most common thyroid malignancy is papillary thyroid cancer (PTC). Mortality rates from PTC mainly depend on its… 
Review
2013
Review
2013
KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.
K-RAS accounts for 90% of RAS mutations in lung adenocarcinomas, the most commonly mutated oncogene in NSCLC, with mutations… 
Review
2012
Review
2012
[Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology].
2012
2012
Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC).
7503 Background: KRAS mutations are the most common (~20%) oncogenic alteration in NSCLC. There are no effective targeted… 
2012
2012
Pharmacodynamic biomarker-driven trial of MK-2206, an AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma (CRC).
3529 Background: The RAF/MEK/ERK and PI3K/AKT signaling pathways are commonly deregulated in CRC. Each can serve as a… 
Highly Cited
2010
Highly Cited
2010
Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines
Selumetinib (AZD6244; ARRY-142886) is a tight-binding, uncompetitive inhibitor of mitogen-activated protein kinase kinases (MEK… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)